Junshi Biosciences Expands Toripalimab Indication to Earlier-Stage Lung Cancer — Shanghai Junshi Biosciences Co., Ltd.

Event summary

Junshi Biosciences' supplemental application for toripalimab plus chemotherapy as perioperative treatment for resectable stage II-III NSCLC accepted by NMPA on July 21, 2026.
NEOTORCH phase 3 study enrolled 501 patients with resectable stage II-III NSCLC, showing significant improvement in event-free survival (EFS) and major pathological response (MPR) rates.
Toripalimab in combination with chemotherapy reduced the risk of disease recurrence or death by 60% compared to chemotherapy alone.
The full results of a post hoc analysis of surgical outcomes were published in JAMA Surgery in July 2026.

The big picture

Junshi Biosciences' expansion of toripalimab's indication to earlier-stage lung cancer aligns with the broader trend of immunotherapy becoming a cornerstone in perioperative treatment strategies. This approval positions toripalimab as a key player in the competitive landscape of PD-1 inhibitors, potentially increasing its market penetration and revenue streams. The strategic significance lies in Junshi Biosciences' ability to differentiate itself through innovative clinical trial designs and robust efficacy data.

What we're watching

Market Expansion: Whether Junshi Biosciences can leverage this approval to expand toripalimab's market share in earlier-stage lung cancer treatment.
Regulatory Dynamics: The pace at which other regulatory bodies approve toripalimab for similar indications globally.
Clinical Efficacy: How the long-term overall survival (OS) data from NEOTORCH will impact toripalimab's adoption as a standard of care.